<DOC>
	<DOCNO>NCT02908906</DOCNO>
	<brief_summary>The Primary purpose study identify recommend Phase 2 dose [ RP2D ( ) ] JNJ-63723283 Part 1 assess anti-tumor activity JNJ-63723283 RP2D ( ) participant select advanced cancer include non-small-cell lung cancer ( NSCLC ) , melanoma , renal , bladder , small-cell lung cancer ( SCLC ) , gastric/esophageal cancer Part 2 .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics , Clinical Activity JNJ-63723283 , Anti-PD-1 Monoclonal Antibody , Participants With Advanced Cancers</brief_title>
	<detailed_description>This First Human ( FIH ) , open-label ( people involve know identity intervention ) , multicenter ( 1 study site ) study participant advance cancer establish recommend Phase 2 dose ( RP2D [ ] ) JNJ-63723283 Part 1 evaluate safety efficacy RP2D ( ) Part 2 . Subject participation include Screening Phase ( 28 Days ) participant eligibility review prior administration first dose JNJ-63723283 ; Treatment Phase start first dose continue treatment discontinue ; Survival Follow-up Phase start upon completion End-of-Treatment Visit end participant completes withdrawal study . The end study define last study assessment last participant study sponsor terminates study , whichever come first . Participants safety monitor throughout study .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have Eastern Cooperative Oncology Group [ ECOG ] performance status 0 1 Has thyroid function laboratory value within normal range Women childbearing potential must negative serum pregnancy test Willing able adhere prohibition restriction specify protocol Participants enrol Part 2 must tumor tissue available correlative study . Fresh tumor biopsy prefer . Archival tissue must meet following criterion : archival section within 4 month section store 2 degree 8 degree Celsius dark archival tumor block within 5 year collection . Participants without tissue meet aforementioned archive tissue criterion must undergo fresh biopsy Has uncontrolled intercurrent illness , include limited ongoing active infection require IV antibiotic , symptomatic congestive heart failure ( New York Heart Association class IIIIV ) , unstable angina pectoris , cardiac arrhythmia , poorly control hypertension diabetes , psychiatric illness/social situation would limit compliance study requirement Has prior treatment antiProgrammedcell death receptor1 ( PD1 ) antibody , antithe ligand programmedcell death 1 ( PDL1 ) antibody antithe ligand programmedcell death 2 ( PDL2 ) antibody Treatment local systemic antineoplastic therapy , radiotherapy ( exclude limit palliative radiation ) , investigational anticancer agent within 14 day 4 halflives , whichever longer , maximum washout period 28 day prior initiation study drug administration Grade 3 high toxicity effect previous treatment immunotherapy A woman pregnant , breastfeeding , plan become pregnant enrolled study within 5 month last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>